TN2009000511A1 - Sulfonyl-quinoline derivatives - Google Patents
Sulfonyl-quinoline derivativesInfo
- Publication number
- TN2009000511A1 TN2009000511A1 TNP2009000511A TN2009000511A TN2009000511A1 TN 2009000511 A1 TN2009000511 A1 TN 2009000511A1 TN P2009000511 A TNP2009000511 A TN P2009000511A TN 2009000511 A TN2009000511 A TN 2009000511A TN 2009000511 A1 TN2009000511 A1 TN 2009000511A1
- Authority
- TN
- Tunisia
- Prior art keywords
- heteroaryl group
- optionally substituted
- mglurl
- substituted phenyl
- sulfonyl
- Prior art date
Links
- FZZUESLMIHSSGS-UHFFFAOYSA-N 2-sulfonyl-1h-quinoline Chemical class C1=CC=C2NC(=S(=O)=O)C=CC2=C1 FZZUESLMIHSSGS-UHFFFAOYSA-N 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0700417A HU0700417D0 (en) | 2007-06-18 | 2007-06-18 | Sulfonyl-quinoline derivatives |
| HU0800376A HUP0800376A2 (en) | 2008-06-12 | 2008-06-12 | Sulfonyl-quinoline derivatives |
| PCT/HU2008/000068 WO2008155588A1 (fr) | 2007-06-18 | 2008-06-17 | Dérivés de la sulfonyle quinoléine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000511A1 true TN2009000511A1 (en) | 2011-03-31 |
Family
ID=89988338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000511A TN2009000511A1 (en) | 2007-06-18 | 2009-12-09 | Sulfonyl-quinoline derivatives |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP2167469B1 (fr) |
| JP (1) | JP5543917B2 (fr) |
| KR (1) | KR101532101B1 (fr) |
| CN (1) | CN101730684B (fr) |
| AU (1) | AU2008264999B8 (fr) |
| BR (1) | BRPI0812816B8 (fr) |
| CA (1) | CA2690079C (fr) |
| CO (1) | CO6311082A2 (fr) |
| CU (1) | CU23822A3 (fr) |
| CY (1) | CY1113251T1 (fr) |
| DK (1) | DK2167469T3 (fr) |
| EA (1) | EA016691B1 (fr) |
| EC (1) | ECSP109884A (fr) |
| ES (1) | ES2392905T3 (fr) |
| GE (1) | GEP20125524B (fr) |
| HK (1) | HK1141009A1 (fr) |
| HR (1) | HRP20120877T1 (fr) |
| IL (1) | IL202463A (fr) |
| MX (1) | MX2009013959A (fr) |
| MY (1) | MY146992A (fr) |
| NI (1) | NI200900217A (fr) |
| NZ (1) | NZ581853A (fr) |
| PL (1) | PL2167469T3 (fr) |
| PT (1) | PT2167469E (fr) |
| RS (1) | RS52495B (fr) |
| SI (1) | SI2167469T1 (fr) |
| TN (1) | TN2009000511A1 (fr) |
| WO (1) | WO2008155588A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2751761A1 (fr) * | 2008-10-22 | 2010-04-29 | House Ear Institute | Traitement therapeutique et/ou prophylactique de pathologies de l'oreille interne par la modulation du recepteur metabotropique du glutamate |
| MY167423A (en) * | 2011-11-03 | 2018-08-27 | Merck Sharp & Dohme | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use |
| RU2500672C1 (ru) * | 2012-10-25 | 2013-12-10 | Андрей Александрович Иващенко | (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения |
| AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| US9932310B2 (en) | 2016-02-08 | 2018-04-03 | City Of Hope | DNA2 inhibitors for cancer treatment |
| KR101893515B1 (ko) * | 2017-06-09 | 2018-08-30 | 영남대학교 산학협력단 | 구리 촉매를 이용한 4-하이드록시-3-설파닐쿠마린 유도체 또는 4-하이드록시-3-설파닐퀴놀리논 유도체의 신규 제조방법 및 이로 제조된 유도체 화합물과 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60004654T2 (de) * | 1999-03-29 | 2004-06-24 | Neurogen Corp., Branford | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| BR0114253A (pt) * | 2000-10-02 | 2003-07-01 | Janssen Pharmaceutica Nv | Antagonistas de receptor de glutamato metabotrópico |
| ATE398108T1 (de) * | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| CA2537141A1 (fr) * | 2003-09-02 | 2005-03-10 | Merck And Co., Inc. | Amines et ethers de bipyridyle utilises comme modulateurs du recepteur 5 metabotropique au glutamate |
| PA8619901A1 (es) * | 2003-12-12 | 2005-11-25 | Wyeth Corp | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| EA200801525A1 (ru) * | 2005-12-20 | 2008-10-30 | Рихтер Гедеон Нирт. | ПРОИЗВОДНЫЕ ХИНОЛИНА, ПРИМЕНИМЫЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРАМИ mGluR5 |
-
2008
- 2008-06-17 JP JP2010512781A patent/JP5543917B2/ja active Active
- 2008-06-17 MY MYPI20095244A patent/MY146992A/en unknown
- 2008-06-17 SI SI200830764T patent/SI2167469T1/sl unknown
- 2008-06-17 ES ES08762671T patent/ES2392905T3/es active Active
- 2008-06-17 EA EA201070025A patent/EA016691B1/ru unknown
- 2008-06-17 MX MX2009013959A patent/MX2009013959A/es active IP Right Grant
- 2008-06-17 NZ NZ581853A patent/NZ581853A/xx unknown
- 2008-06-17 CA CA2690079A patent/CA2690079C/fr active Active
- 2008-06-17 PT PT08762671T patent/PT2167469E/pt unknown
- 2008-06-17 CN CN2008800207550A patent/CN101730684B/zh active Active
- 2008-06-17 AU AU2008264999A patent/AU2008264999B8/en active Active
- 2008-06-17 DK DK08762671.9T patent/DK2167469T3/da active
- 2008-06-17 KR KR1020097025394A patent/KR101532101B1/ko active IP Right Grant
- 2008-06-17 GE GEAP200811651A patent/GEP20125524B/en unknown
- 2008-06-17 WO PCT/HU2008/000068 patent/WO2008155588A1/fr active Application Filing
- 2008-06-17 RS RS20120457A patent/RS52495B/en unknown
- 2008-06-17 PL PL08762671T patent/PL2167469T3/pl unknown
- 2008-06-17 EP EP08762671A patent/EP2167469B1/fr active Active
- 2008-06-17 BR BRPI0812816A patent/BRPI0812816B8/pt active IP Right Grant
-
2009
- 2009-12-02 IL IL202463A patent/IL202463A/en active IP Right Grant
- 2009-12-09 TN TNP2009000511A patent/TN2009000511A1/fr unknown
- 2009-12-15 NI NI200900217A patent/NI200900217A/es unknown
- 2009-12-16 CU CU20090219A patent/CU23822A3/es active IP Right Grant
-
2010
- 2010-01-15 CO CO10003762A patent/CO6311082A2/es active IP Right Grant
- 2010-01-18 EC EC2010009884A patent/ECSP109884A/es unknown
- 2010-07-20 HK HK10107003.8A patent/HK1141009A1/xx unknown
-
2012
- 2012-10-25 CY CY20121101007T patent/CY1113251T1/el unknown
- 2012-10-30 HR HRP20120877AT patent/HRP20120877T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000511A1 (en) | Sulfonyl-quinoline derivatives | |
| JOP20200338A1 (ar) | عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| NO20063452L (no) | Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler | |
| MY146532A (en) | Thiazole derivative | |
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| MY139887A (en) | Tetrahydronaphthyridine derivatives and a process for preparing the same. | |
| EP2597088A4 (fr) | Antagoniste des récepteurs p2x4 | |
| MX2009008665A (es) | Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa. | |
| MX2009010909A (es) | Derivados de ftalazino y su uso como medicamento para tratar el cancer. | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| WO2008087611A3 (fr) | Dérivés de pyrrolidine et de piperidine | |
| MX2009011769A (es) | Derivados de piridona como inhibidores de mapk p38a. | |
| TW200609223A (en) | Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives | |
| EP1854789A4 (fr) | Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase | |
| MA33131B1 (fr) | Nouveaux derives de benzothiadiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| WO2008006969A3 (fr) | Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EA200801536A1 (ru) | Новые тиенопирсульфоновые производные | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| ATE396183T1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| MX338631B (es) | 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| HRP20110785T8 (en) | Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands | |
| RS54248B1 (en) | NEW UNITS AS LISTS OF HISTAMINE H3 RECEPTORS | |
| TNSN08161A1 (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof |